| Name | Title | Contact Details |
|---|
Cerami is a Belleville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mosaic is a whole-person healthcare organization reaching across 11 states and providing supports to more than 4,500 people. Services empower people with disabilities, mental and behavioral health needs and autism, as well as aging adults to live their best life. Mosaic is an affiliated social ministry organization of the Evangelical Lutheran Church in America and a member of Lutheran Services in America. Mosaic is a nonprofit 501(c)(3) organization.
Avamere Family of Companies, a group of independent privately owned post-acute care companies, is dedicated to seniors` health and well-being. We take great pride in offering a continuum of care, which allows seniors to stay independent and active.
KARL STORZ Veterinary Endoscopy is a Goleta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.